Data from A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine

Autor: Tito Fojo, Susan E. Bates, Olaf Van Tellingen, Frank Balis, Barry Goldspiel, Andrew Dwyer, Rob Robey, Susan Bakke, Ann Rutt, Clara Chen, Richard Wilson, Maureen Edgerly, Jame Abraham

Purpose: P-glycoprotein (Pgp) antagonists have had unpredictable pharmacokinetic interactions requiring reductions of chemotherapy. We report a phase I study using tariquidar (XR9576), a potent Pgp antagonist, in combination with vinorelbine.Experime

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d530611d13c96f5fb5d2ab30697e39e
https://doi.org/10.1158/1078-0432.c.6517044

Engraftment of MDR1 and NeoR Gene-Transduced Hematopoietic Cells After Breast Cancer Chemotherapy

Autor: Ira Pastan, Michael M. Gottesman, Kenneth H. Cowan, David Venzon, Susan F. Leitman, Barry Goldspiel, Stephanie Sellers, Yawen Chiang, Charles Carter, Brian Sorrentino, Cathy Chow, Hui Huang, Cynthia E. Dunbar, Georgie Cusack, Andrea Abati, Elizabeth J. Read, Jeffrey A. Moscow, Jo Anne Zujewski, Kenneth Hines

Publikováno v: Blood. 94:52-61

To determine whether the multidrug resistance gene MDR1could act as a selectable marker in human subjects, we studied engraftment of peripheral blood progenitor cells (PBPCs) transduced with either MDR1 or the bacterial NeoR gene in six breast cancer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd12aeeacea0914558de803b9500284f
https://doi.org/10.1182/blood.v94.1.52.413k35_52_61

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms

Autor: Victor, Sandor, Susan, Bakke, Robert W, Robey, Min H, Kang, Mikhail V, Blagosklonny, Jonathon, Bender, Rebecca, Brooks, Richard L, Piekarz, Eben, Tucker, William D, Figg, Kenneth K, Chan, Barry, Goldspiel, Antonio Tito, Fojo, Stanley P, Balcerzak, Susan E, Bates

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 8(3)

The primary objectives of this trial were to define the maximum tolerated dose (MTD) and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given on a day-1 and day-5 schedule every 21 days. A secondary objective of the tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::2502edaa2da47ce5fe7ab228c01b2111
https://pubmed.ncbi.nlm.nih.gov/25979924

ASHP guidelines on preventing medication errors with chemotherapy and biotherapy.

Autor: Goldspiel B; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Hoffman JM; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Griffith NL; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Goodin S; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., DeChristoforo R; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Montello CM; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Chase JL; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Bartel S; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health., Patel JT; Barry Goldspiel, Pharm.D., BCPS, BCOP, FASHP, FISOPP, is Chief, Clinical Pharmacy Specialist Section, Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, MD. James M. Hoffman, Pharm.D., M.S., BCPS, is Medication Outcomes and Safety Officer, Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN. Niesha L. Griffith, M.S., FASHP, is Director of Pharmacy and Infusion Services, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus. Susan Goodin, Pharm.D., BCOP, FASHP, FCCP, is Executive Director, Statewide Affairs, Rutgers Cancer Institute of New Jersey, New Brunswick, and Professor of Medicine, Division of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick. Robert DeChristoforo, M.S., FASHP, is Chief, Clinical Center Pharmacy Department, National Institutes of Health. CAPT Michael Montello, Pharm.D., M.B.A., is Associate Branch Chief for Clinical Trials Technology and Pharmacist Consultant, Clinical Investigations Branch, National Cancer Institute (NCI) Cancer Therapy Evaluation Program, Bethesda, and Project Officer, NCI Cancer Trials Support Unit, Bethesda. Judy L. Chase, Pharm.D., FASHP, is Director, Clinical Pharmacy Services, University of Texas M. D. Anderson Cancer Center, Houston. Sylvia Bartel, M.P.H., is Director of Pharmacy and Clinical Support Services, Dana-Farber Cancer Institute, Boston, MA. Jharana Tina Patel, Pharm.D., is Quality Assurance Officer, Clinical Center, National Institutes of Health.

Publikováno v: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists [Am J Health Syst Pharm] 2015 Apr 15; Vol. 72 (8), pp. e6-e35.